Literature DB >> 18491963

Hallucinations during voriconazole therapy.

Dimitrios I Zonios1, Juan Gea-Banacloche, Richard Childs, John E Bennett.   

Abstract

As part of a prospective natural history cohort study of voriconazole toxicity, we describe the characteristics of 12 of 72 voriconazole-treated patients who experienced hallucinations from March 2006 through November 2007. Hallucinations associated with voriconazole use are not uncommon. Doctors should be aware of this complication, and the recipients of the drug should be reassured that the hallucinations are an effect of the drug.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18491963      PMCID： PMC2727751          DOI： 10.1086/588844

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  11 in total

1.  Development and validation of a high-performance liquid chromatography assay for voriconazole.

Authors:  Gennethel J Pennick; Martin Clark; Deanna A Sutton; Michael G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

2.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

Authors:  Thomas J Walsh; Peter Pappas; Drew J Winston; Hillard M Lazarus; Finn Petersen; John Raffalli; Saul Yanovich; Patrick Stiff; Richard Greenberg; Gerald Donowitz; Mindy Schuster; Annette Reboli; John Wingard; Carola Arndt; John Reinhardt; Susan Hadley; Robert Finberg; Michél Laverdière; John Perfect; Gary Garber; Giuseppe Fioritoni; Eli Anaissie; Jeanette Lee
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

3.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.

Authors:  David W Denning; Patricia Ribaud; Noel Milpied; Denis Caillot; Raoul Herbrecht; Eckhard Thiel; Andrea Haas; Markus Ruhnke; Hartmut Lode
Journal:  Clin Infect Dis       Date:  2002-01-22       Impact factor: 9.079

4.  Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring.

Authors:  Alexander Imhof; Dominik J Schaer; Urs Schanz; Urs Schwarz
Journal:  Swiss Med Wkly       Date:  2006-11-11       Impact factor: 2.193

5.  Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.

Authors:  B J Kullberg; J D Sobel; M Ruhnke; P G Pappas; C Viscoli; J H Rex; J D Cleary; E Rubinstein; L W P Church; J M Brown; H T Schlamm; I T Oborska; F Hilton; M R Hodges
Journal:  Lancet       Date:  2005 Oct 22-28       Impact factor: 79.321

6.  A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.

Authors:  R Ally; D Schürmann; W Kreisel; G Carosi; K Aguirrebengoa; B Dupont; M Hodges; P Troke; A J Romero
Journal:  Clin Infect Dis       Date:  2001-09-26       Impact factor: 9.079

7.  Voriconazole-induced musical hallucinations.

Authors:  A K Agrawal; L K Sherman
Journal:  Infection       Date:  2004-10       Impact factor: 3.553

8.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

9.  Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database.

Authors:  Céline Eiden; Hélène Peyrière; Marylène Cociglio; Samira Djezzar; Sylvie Hansel; Jean-Pierre Blayac; Dominique Hillaire-Buys
Journal:  Ann Pharmacother       Date:  2007-04-24       Impact factor: 3.154

10.  Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study.

Authors:  Nina Singh; Ajit P Limaye; Graeme Forrest; Nasia Safdar; Patricia Muñoz; Kenneth Pursell; Sally Houston; Fernando Rosso; Jose G Montoya; Pamela Patton; Ramon Del Busto; Jose M Aguado; Robert A Fisher; Goran B Klintmalm; Rachel Miller; Marilyn M Wagener; Russell E Lewis; Dimitrios P Kontoyiannis; Shahid Husain
Journal:  Transplantation       Date:  2006-02-15       Impact factor: 4.939
View more
  30 in total

1.  Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

Authors:  Thomas J Walsh; Timothy Driscoll; Peter A Milligan; Nolan D Wood; Haran Schlamm; Andreas H Groll; Hasan Jafri; Antonio C Arrieta; Nigel J Klein; Irja Lutsar
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

2.  Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.

Authors:  Elizabeth H Doby; Daniel K Benjamin; Anne J Blaschke; Robert M Ward; Andrew T Pavia; Paul L Martin; Timothy A Driscoll; Michael Cohen-Wolkowiez; Cassandra Moran
Journal:  Pediatr Infect Dis J       Date:  2012-06       Impact factor: 2.129

3.  Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.

Authors:  Brad Moriyama; Sameer Kadri; Stacey A Henning; Robert L Danner; Thomas J Walsh; Scott R Penzak
Journal:  Curr Fungal Infect Rep       Date:  2015-04-16

4.  What is the role of therapeutic drug monitoring in antifungal therapy?

Authors:  Jeannina A Smith
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

5.  Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.

Authors:  Dimitrios Zonios; Hiroshi Yamazaki; Norie Murayama; Ven Natarajan; Tara Palmore; Richard Childs; Jeff Skinner; John E Bennett
Journal:  J Infect Dis       Date:  2014-01-07       Impact factor: 5.226

6.  Repeated antifungal use audits are essential for selecting the targets for intervention in antifungal stewardship.

Authors:  Maricela Valerio; Antonio Vena; Carmen Guadalupe Rodríguez-González; Esther Chamorro de Vega; Miriam Mateos; Maria Sanjurjo; Emilio Bouza; Patricia Muñoz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-08-04       Impact factor: 3.267

7.  Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.

Authors:  Claudia Michael; Uta Bierbach; Katrin Frenzel; Thoralf Lange; Nadezda Basara; Dietger Niederwieser; Christine Mauz-Körholz; Rainer Preiss
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

8.  Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.

Authors:  Gloria N Mattiuzzi; Jorge Cortes; Gladys Alvarado; Srdan Verstovsek; Charles Koller; Sherry Pierce; Deborah Blamble; Stefan Faderl; Lianchun Xiao; Mike Hernandez; Hagop Kantarjian
Journal:  Support Care Cancer       Date:  2009-12-03       Impact factor: 3.603

9.  Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.

Authors:  J Kevin Hicks; Kristine R Crews; Patricia Flynn; Cyrine E Haidar; Calvin C Daniels; Wenjian Yang; John C Panetta; Deqing Pei; Jeffrey R Scott; Alejandro R Molinelli; Ulrich Broeckel; Deepa Bhojwani; William E Evans; Mary V Relling
Journal:  Pharmacogenomics       Date:  2014-06       Impact factor: 2.533

Review 10.  Management of invasive aspergillosis in patients with COPD: rational use of voriconazole.

Authors:  Florence Ader; Anne-Lise Bienvenu; Blandine Rammaert; Saad Nseir
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.